30.07.2010 • News

Wacker Ends Q2 2010 with New Sales Record

Wacker Chemie ended Q2 2010 with a new sales record, primarily thanks to much higher sales volumes. Q2 2010 sales climbed 30% to €1,202.0 million (Q2 2009: €925.5 million). Growth was additionally driven by the stronger US dollar. In contrast, lower prices slowed the sales increase to some extent.

Wacker also posted clear earnings gains compared to both a year ago and Q1 2010. Earnings before interest, taxes, depreciation and amortization (Ebitda) in Q2 climbed to €308.6 million (Q2 2009: €170.1 million) up over 81% on the prior year, Ebitda rose at more than double the rate of sales.

Company

Logo:

Wacker Chemie

Hanns-Seidel-Platz 4
81737 Munich
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read